@BioTechHealthX

BioTech Health X delivers the latest biotechnology news, health coverage, genomics, biotech news and stock analysis keeping you informed on the sector.

 United States
BioTechHealthX.com
Joined April 2021
  • Tweets969
  • Following378
  • Followers989
7Media
$ISRG @IntuitiveSurg reported 19% second-quarter revenue growth and a larger installed base. Here’s why it tops the ranking—and why the share price still matters. biotechhealthx.com/biotech-n…

Intuitive Surgical (ISRG) Is No. 1 in Medical Robotics—Should Investors Chase It?

Intuitive Surgical reported 19% second-quarter revenue growth and a larger installed base. Here’s why it tops the ranking—and why the share price still matters.

biotechhealthx.com
1
62
$SYK Stryker’s Mako has an established place in orthopedic surgery. With more applications across its robotics portfolio, investors must weigh adoption against SYK’s valuation. biotechhealthx.com/biotech-n…

One Robot, More Procedures: Stryker (SYK)’s Mako Bet Gets Bigger

Stryker’s Mako has an established place in orthopedic surgery. With more applications across its robotics portfolio, investors must weigh adoption against SYK’s valuation.

biotechhealthx.com
34
$MDT @Medtronic has the scale to compete in robotic surgery, but placements alone will not settle the case. Here’s why procedure growth and hospital use matter for MDT stock. biotechhealthx.com/biotech-n…

Medtronic (MDT) Has a Hugo Surgical Robot. Can Hospitals Keep It Busy?

Medtronic has the scale to compete in robotic surgery, but placements alone will not settle the case. Here’s why procedure growth and hospital use matter for MDT stock.

biotechhealthx.com
1
78
$PRCT @PROCEPTRobotics' second-quarter revenue rose 19% to $94.5 million, but its net loss widened to $26.9 million. Here’s the tension behind this focused medical robotics stock. biotechhealthx.com/biotech-n…

PROCEPT (PRCT) Has a Robot, a Growth Story, and a $26.9M Problem

PROCEPT’s second-quarter revenue rose 19% to $94.5 million, but its net loss widened to $26.9 million. Here’s the tension behind this focused medical robotics stock.

biotechhealthx.com
82
$ZBH @zimmerbiomet already sells the ROSA surgical robotics platform. Now it is preparing for a Monogram robot launch expected in 2027. Here is what investors should watch next. biotechhealthx.com/biotech-n…

Zimmer Biomet (ZBH) Has a New Robot Coming. Can It Deliver?

Zimmer Biomet already sells the ROSA surgical robotics platform. Now it is preparing for a Monogram robot launch expected in 2027. Here is what investors should watch next.

biotechhealthx.com
1
53
$GMED @GlobusMedical reported 6% overall revenue growth in the second quarter of 2026. Its expanding surgical platform adds intrigue, but competition still matters. biotechhealthx.com/biotech-n…

Globus Medical (GMED): A 6% Growth Quarter and a Robotics Wild Card

Globus Medical reported 6% overall revenue growth in the second quarter of 2026. Its expanding surgical platform adds intrigue, but competition still matters.

biotechhealthx.com
50
$JNJ @OTTAVA gives @JNJNews a place in soft tissue robotic surgery. FDA authorization opened the door, but hospital budgets, surgeon training and procedure volume will shape its launch. biotechhealthx.com/biotech-n…

Johnson & Johnson (JNJ) Just Entered the Surgical Robot Race. Here’s the Catch

OTTAVA gives Johnson & Johnson a place in soft tissue robotic surgery. FDA authorization opened the door, but hospital budgets, surgeon training and procedure volume will shape its launch.

biotechhealthx.com
1
47
$BDX Becton Dickinson says Fairview Health Services is deploying its Vmax 160 pharmacy robot. Here’s what the rollout means for its automation business—and why BDX is a broader bet. biotechhealthx.com/biotech-n…

Becton Dickinson (BDX)’s Pharmacy Robot Just Got a Real-World Test: Is This A Great Investment...

BD says Fairview Health Services is deploying its Vmax 160 pharmacy robot. Here’s what the rollout means for its automation business—and why BDX is a broader bet.

biotechhealthx.com
42
$SSII At the stated price as of writing, @SSINNOVATIONS_ offers direct exposure to surgical robotics. Its shorter track record, funding needs and execution risks deserve equal attention. biotechhealthx.com/biotech-n…

SS Innovations (SSII) at $2.95: A Surgical Robotics Opportunity With a Catch

At the stated price as of writing, SS Innovations offers direct exposure to surgical robotics. Its shorter track record, funding needs and execution risks deserve equal attention.

biotechhealthx.com
38
$ARAY @Accuray's CyberKnife gives this low priced medical robotics stock an unusual angle. See what its RaySearch collaboration could mean and why investors still face substantial risk. biotechhealthx.com/biotech-n…

Accuray (ARAY) Costs Just 22 Cents. Is Its Cancer Robot Worth a Closer Look?

Accuray’s CyberKnife gives this low priced medical robotics stock an unusual angle. See what its RaySearch collaboration could mean and why investors still face substantial risk.

biotechhealthx.com
88
$CVM A keynote will spotlight @CelSciCorp's head and neck cancer data. The real question for investors is whether a new 212-patient study can repeat the earlier finding. biotechhealthx.com/biotech-n…

CEL-SCI (CVM)’s 73% Survival Finding Gets a Global Spotlight

A keynote will spotlight CEL-SCI’s head and neck cancer data. The real question for investors is whether a new 212-patient study can repeat the earlier finding.

biotechhealthx.com
99
$ISRG $PRCT $MDT $SYK $ZBH Medical robots do far more than assist surgeons. This countdown covers surgical robotics, pharmacy automation and robotic radiotherapy stocks for 2026. biotechhealthx.com/biotech-n…

Top 5 Medical Robotics Stocks to Buy Today

Medical robots do far more than assist surgeons. This countdown covers surgical robotics, pharmacy automation and robotic radiotherapy stocks for 2026.

biotechhealthx.com
169
$ARAY $SSII $BDX $GMED $JNJ Surgical robots get the headlines, but pharmacy automation and robotic cancer treatment belong in the conversation too. See which 10 stocks made the best medical stocks ranking. biotechhealthx.com/biotech-n…

Top 10 Medical Robotics Stocks to Buy Today

Surgical robots get the headlines, but pharmacy automation and robotic cancer treatment belong in the conversation too. See which 10 stocks made the best medical stocks ranking.

biotechhealthx.com
74
$TEM Potential Medicare reimbursement for @TempusShop AI’s liquid-biopsy test could reach $250 million to $300 million in 2027—but approval and execution risks remain. biotechhealthx.com/biotech-n…

The No. 1 AI Healthcare Stock Has a $300M Catalyst Hiding in Plain Sight: Tempus AI (TEM)

Potential Medicare reimbursement for Tempus AI’s liquid-biopsy test could reach $250 million to $300 million in 2027—but approval and execution risks remain.

biotechhealthx.com
89
$NTRA Natera, Inc. (NASDAQ: NTRA) ranks second among healthcare AI stocks after posting rapid revenue growth, record testing volumes and improving financial performance. biotechhealthx.com/biotech-n…

Natera (NTRA) Nearly Took the Top Spot—Its 38% Revenue Growth Explains Why

Natera, Inc. (NASDAQ: NTRA) ranks second among healthcare AI stocks after posting rapid revenue growth, record testing volumes and improving financial performance.

biotechhealthx.com
1
100
$GH Screening revenue surged more than 250% for @GuardantHealth, Inc. (NASDAQ: GH), fueled by rising Shield adoption and demand for blood-based cancer testing. biotechhealthx.com/biotech-n…

Guardant Health (GH)’s Screening Revenue Exploded 250%!

Screening revenue surged more than 250% for Guardant Health, Inc. (NASDAQ: GH), fueled by rising Shield adoption and demand for blood-based cancer testing.

biotechhealthx.com
1
121
$ISRG Intuitive Surgical, Inc. (NASDAQ: ISRG) offers profitability, recurring revenue and robotic-surgery leadership, but investors may be paying heavily for that quality. biotechhealthx.com/biotech-n…

Intuitive Surgical (ISRG) Is Profitable, Powerful and Pricey—Is It Still a Buy?

Intuitive Surgical, Inc. (NASDAQ: ISRG) offers profitability, recurring revenue and robotic-surgery leadership, but investors may be paying heavily for that quality.

biotechhealthx.com
1
99
$RDNT @RadNet’s AI-powered DeepHealth division is growing faster than its core imaging business. See what could make RDNT stock increasingly attractive. biotechhealthx.com/biotech-i…

RadNet (RDNT)’s DeepHealth Business Just Grew 56.5%!

RadNet’s AI-powered DeepHealth division is growing faster than its core imaging business. See what could make RDNT stock increasingly attractive.

biotechhealthx.com
1
2
130
$OSCR @OscarHealth, Inc. (NYSE: OSCR) posted $4.88 billion in quarterly revenue, returned to profitability and raised its forecast—but major policy risks remain. biotechhealthx.com/biotech-n…

Oscar Health (OSCR) Revenue Just Soared 70%!

Oscar Health, Inc. (NYSE: OSCR) posted $4.88 billion in quarterly revenue, returned to profitability and raised its forecast—but major policy risks remain.

biotechhealthx.com
1
122
$HIMS Hims & Hers Health, Inc. (NYSE: HIMS) delivered explosive revenue and subscriber growth, but falling margins and weight-loss drug regulations could complicate its next chapter. biotechhealthx.com/biotech-n…

Hims & Hers (HIMS) Just Hit $753 Million in Revenue; Can it Keep Growing?

Hims & Hers Health, Inc. (NYSE: HIMS) delivered explosive revenue and subscriber growth, but falling margins and weight-loss drug regulations could complicate its next chapter.

biotechhealthx.com
1
110
Load more